- Trials with a EudraCT protocol (130)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
130 result(s) found for: Natural products.
Displaying page 3 of 7.
EudraCT Number: 2012-002414-39 | Sponsor Protocol Number: MK-3102-018 | Start Date*: 2013-01-04 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005061-13 | Sponsor Protocol Number: A011-12 | Start Date*: 2021-06-22 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003203-32 | Sponsor Protocol Number: 3115A1-3307-WW | Start Date*: 2009-04-17 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OST... | |||||||||||||
Medical condition: Menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003142-32 | Sponsor Protocol Number: TBR-760-NFPA-201 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:Tiburio Therapeutics, Inc. | |||||||||||||
Full Title: A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas | |||||||||||||
Medical condition: Non-Functioning Pituitary Adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019522-13 | Sponsor Protocol Number: GP13-301 | Start Date*: 2011-10-07 | ||||||||||||||||
Sponsor Name:HEXAL AG (a Sandoz company) | ||||||||||||||||||
Full Title: A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophospham... | ||||||||||||||||||
Medical condition: Advanced stage follicular lymphoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) PT (Completed) FR (Completed) HU (Completed) DE (Completed) AT (Completed) BG (Completed) ES (Completed) PL (Completed) GR (Completed) IT (Completed) GB (Completed) IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003190-34 | Sponsor Protocol Number: ACE-536-MDS-002 | Start Date*: 2019-01-02 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Ris... | |||||||||||||
Medical condition: Myelodysplastic syndrome (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000199-12 | Sponsor Protocol Number: A011-13 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Prematurely Ended) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001699-20 | Sponsor Protocol Number: 042011 | Start Date*: 2012-05-18 |
Sponsor Name:St. Anna Kinderkrebsforschung, GmbH | ||
Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS | ||
Medical condition: Langerhans cell histiocytosis | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002781-31 | Sponsor Protocol Number: PQBirch301 | Start Date*: 2017-02-16 | |||||||||||
Sponsor Name:Allergy Therapeutics (UK) Ltd | |||||||||||||
Full Title: A multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Birch Modified Allergen Tyrosine adsorbed + MPL in the prevention of season... | |||||||||||||
Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004475-39 | Sponsor Protocol Number: 73763989HPB2003 | Start Date*: 2020-09-21 | |||||||||||
Sponsor Name:Janssen Sciences Ireland Unlimited Company | |||||||||||||
Full Title: A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002125-68 | Sponsor Protocol Number: IM103-045 | Start Date*: 2007-11-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients Revised Protocol Number 04, incorporating Amendments 02, 03, 04 and 05 (version 10.0 dated 20-Nov-0... | ||||||||||||||||||
Medical condition: First time recipient of a deceased donor liver transplant | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004527-31 | Sponsor Protocol Number: GS-US-196-0103 | Start Date*: 2008-12-12 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... | |||||||||||||
Medical condition: Genotype-1 Chronic Hepatitis C Virus (HCV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012389-30 | Sponsor Protocol Number: Myoblast/ISD/EKS01 | Start Date*: 2009-10-02 | ||||||||||||||||
Sponsor Name:University Medical Centre Ljubljana, Department of Gynaecology | ||||||||||||||||||
Full Title: Transurethral ultrasound-directed injection of autologous myoblasts in combination with functional electrical stimulation in patients with intrinsic urinary sphincter deficiency. | ||||||||||||||||||
Medical condition: Stress urinary incontinence due to intrinsic sphincter deficiency (ISD). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: SI (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002612-10 | Sponsor Protocol Number: MK-3102-022 | Start Date*: 2013-04-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have ... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003333-25 | Sponsor Protocol Number: 804P301 | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:Supernus Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Ad... | |||||||||||||
Medical condition: Treatment of seizures of partial origin in subjects with refractory epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002911-33 | Sponsor Protocol Number: ABT-gpASIT011 | Start Date*: 2018-12-18 | |||||||||||
Sponsor Name:ASIT biotech S.A. | |||||||||||||
Full Title: A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass p... | |||||||||||||
Medical condition: Treatment of seasonal grass pollen-induced rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020177-16 | Sponsor Protocol Number: CQAW039A2201 | Start Date*: 2011-01-28 | |||||||||||
Sponsor Name:NOVARTIS PHARMA SERVICES AG | |||||||||||||
Full Title: A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma | |||||||||||||
Medical condition: Mild to moderate persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) BG (Prematurely Ended) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009888-60 | Sponsor Protocol Number: CLCQ908A2203 | Start Date*: 2009-07-20 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5... | |||||||||||||
Medical condition: Type II Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed) BE (Completed) PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000737-39 | Sponsor Protocol Number: AD04-301 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:Adial Pharmaceuticals Inc. | |||||||||||||
Full Title: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults with A... | |||||||||||||
Medical condition: Adult patients diagnosed with moderate or severe alcohol use disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) BG (Completed) PL (Completed) EE (Completed) LV (Completed) HR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000301-23 | Sponsor Protocol Number: MK-3102-027 | Start Date*: 2013-08-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Ina... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) IT (Prematurely Ended) AT (Completed) BE (Prematurely Ended) SK (Completed) ES (Completed) DE (Completed) EE (Prematurely Ended) BG (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
